ConstIpatIon, HepatIc encephalopathy
Lactitol Monohydrate is a disaccharide derivatives consisting of galactose and sorbitol, which is only minimally absorbed and is not hydrolysed by the disaccharidases of the GIT and thus reaches the colon unchanged. In the colon it is broken down to short chain low molecular weight organic acids by the intestinal flora, resulting in an increase in osmotic pressure in the colon, thereby causing an increase in the stool water content and stool volume, which explains the laxative effect. Lactitol Monohydrate produces its effect in the lumen of the colon, where it is virtually 100% bioavailable. It is absorbed only in minimal amounts. Up to 2% can be found unchanged in the urine.
2 teaspoonfuls (20 gm) once or twice daily with plenty of water
Antacids and neomycin should not be given simultaneously with Lactitol to cirrhotic patients with portal systemic encephalopathy. Lactitol may increase potassium loss caused by other drugs e.g. thiazide diuretics, corticosteroids, carbenoxolone, amphotericin B and it may enhance the risk of toxic effects of glycosides in patients receiving concomitant therapy.
Patients with known hypersensitivity to any of the active substance. Gastro-intestinal obstruction. Galactosaemia.
Abdominal distension, flatulance
Pregnancy Category - Not Classified. FDA has not yet classified the drug into a specified pregnancy category.
Store in a cool, dry place and away from light. Keep out of reach of children.
.png&w=384&q=75)